LHX vs TMO
L3harris Technologies, Inc. and Thermo Fisher Scientific Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | LHX | TMO |
|---|---|---|
| Revenue | $21.9B | $44.6B |
| Net income | $1.6B | $6.7B |
| Gross margin | · | · |
| Net margin | 7.3% | 15.1% |
| Return on equity | 8.2% | 13.0% |
| Diluted EPS | $8.53 | $17.74 |
| Dividend / share | $4.80 | $1.72 |
| Payout ratio | 56.2% | 9.5% |
| Free cash flow | $2.7B | $6.3B |
| Equity | $19.6B | $53.4B |
| Net debt / equity | 0.48× | 0.62× |
| Current ratio | 1.19× | 1.89× |
| Revenue CAGR 5y | 3.7% | 6.7% |
| Profit CAGR 5y | 7.5% | · |
TMO bills 2.0× the revenue of LHX, and keeps more of each dollar of revenue as profit (15.1% against 7.3%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | LHX | TMO |
|---|---|---|
| FY2025 | $21.9B | $44.6B |
| FY2024 | $21.3B | $42.9B |
| FY2023 | $19.4B | $42.9B |
| FY2022 | $17.1B | $44.9B |
| FY2021 | $17.8B | $39.2B |
| FY2020 | $18.2B | $32.2B |
| FY2019 | $12.9B | $25.5B |
| FY2018 | $6.8B | $24.4B |
| FY2017 | $6.2B | $20.9B |
| FY2016 | $5.9B | $18.3B |
Bottom line
| Fiscal year | LHX | TMO |
|---|---|---|
| FY2025 | $1.6B | $6.7B |
| FY2024 | $1.5B | $6.3B |
| FY2023 | $1.2B | $6.0B |
| FY2022 | $1.1B | $7.0B |
| FY2021 | $1.8B | $7.7B |
| FY2020 | $1.1B | $6.4B |
| FY2019 | $1.3B | $3.7B |
| FY2018 | $949.0M | $2.9B |
| FY2017 | $699.0M | $2.2B |
| FY2016 | $543.0M | $2.0B |
17 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$22,691,000,000 | TMO |
| FY2024 | −$21,554,000,000 | TMO |
| FY2023 | −$23,438,000,000 | TMO |
| FY2022 | −$27,853,000,000 | TMO |
| FY2021 | −$21,397,000,000 | TMO |
| FY2020 | −$14,024,000,000 | TMO |
| FY2019 | −$12,686,000,000 | TMO |
| FY2018 | −$17,557,000,000 | TMO |
| FY2017 | −$14,750,000,000 | TMO |
| FY2016 | −$12,377,000,000 | TMO |
| FY2014 | −$13,004,600,000 | TMO |
| FY2013 | −$8,078,300,000 | TMO |
| FY2012 | −$7,397,900,000 | TMO |
| FY2011 | −$6,107,500,000 | TMO |
| FY2010 | −$10,203,900,000 | TMO |
| FY2008 | −$5,493,000,000 | TMO |
| FY2007 | −$5,150,300,000 | TMO |
TMO has reported the higher revenue in every one of these 17 fiscal years. The gap has widened since the earliest year compared.
17 of 19 comparable fiscal years — a year missing data on either side is not counted.
13 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −7.7 pp | TMO |
| FY2024 | −7.7 pp | TMO |
| FY2023 | −7.7 pp | TMO |
| FY2022 | −9.3 pp | TMO |
| FY2021 | −9.4 pp | TMO |
| FY2020 | −13.8 pp | TMO |
| FY2019 | −4.0 pp | TMO |
| FY2013 | +0.9 pp | LHX |
| FY2012 | −7.3 pp | TMO |
| FY2011 | −11.0 pp | TMO |
| FY2010 | +300.3 pp | LHX |
| FY2008 | −11.8 pp | TMO |
| FY2007 | +1.8 pp | LHX |
The higher net margin has changed hands between LHX and TMO over this period.
13 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LHX's net margin has been more volatile than TMO's over the 13 comparable fiscal years — 81.1 percentage points of standard deviation against 3.8.
13 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between LHX and TMO over these 13 fiscal years — LHX led in 3 and TMO in 10.
13 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LHX's return on equity has been more volatile than TMO's over the 17 comparable fiscal years — 8.9 percentage points of standard deviation against 4.3.
17 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between LHX and TMO over these 17 fiscal years — LHX led in 7 and TMO in 10.
17 of 19 comparable fiscal years — a year missing data on either side is not counted.